Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126007402 | 12600740 | 2 | F | 20160710 | 20160727 | 20160727 | 20160803 | EXP | US-EXELIXIS-CABO-16006167 | EXELIXIS | 72.07 | YR | M | Y | 0.00000 | 20160803 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126007402 | 12600740 | 1 | PS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 60 MG, QD | N | 203756 | 60 | MG | CAPSULE | QD | |||||
| 126007402 | 12600740 | 2 | SS | COMETRIQ | CABOZANTINIB S-MALATE | 1 | Oral | 40 MG, QD | N | 203756 | 40 | MG | CAPSULE | QD | |||||
| 126007402 | 12600740 | 3 | SS | MORPHINE SULFATE. | MORPHINE SULFATE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 4 | C | SIMVASTATIN. | SIMVASTATIN | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 5 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 6 | C | FENOFIBRIC ACID. | FENOFIBRIC ACID | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 7 | C | LISINOPRIL. | LISINOPRIL | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 8 | C | ASPIRIN. | ASPIRIN | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 9 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 10 | C | ALFUZOSIN | ALFUZOSIN | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 11 | C | METOPROLOL. | METOPROLOL | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 12 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 13 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 14 | C | MAGNESIUM | MAGNESIUM | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 15 | C | POTASSIUM | POTASSIUM | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 16 | C | CYCLOBENZAPRINE | CYCLOBENZAPRINE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 17 | C | ACETAMINOPHEN AND CODEINE | ACETAMINOPHENCODEINE PHOSPHATE | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 18 | C | NITROSTAT | NITROGLYCERIN | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 19 | C | ZOMETA | ZOLEDRONIC ACID | 1 | U | 0 | |||||||||||
| 126007402 | 12600740 | 20 | C | DIPHENOXYLATE/ATROPINE | ATROPINEDIPHENOXYLATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126007402 | 12600740 | 1 | Renal cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126007402 | 12600740 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126007402 | 12600740 | Agitation | |
| 126007402 | 12600740 | Decreased appetite | |
| 126007402 | 12600740 | Dehydration | |
| 126007402 | 12600740 | Diarrhoea | |
| 126007402 | 12600740 | Dysgeusia | |
| 126007402 | 12600740 | Dysphonia | |
| 126007402 | 12600740 | Fatigue | |
| 126007402 | 12600740 | Haemoglobin decreased | |
| 126007402 | 12600740 | Hair colour changes | |
| 126007402 | 12600740 | Nausea | |
| 126007402 | 12600740 | Off label use | |
| 126007402 | 12600740 | Pain | |
| 126007402 | 12600740 | Renal impairment | |
| 126007402 | 12600740 | Vomiting | |
| 126007402 | 12600740 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126007402 | 12600740 | 1 | 20160303 | 20160630 | 0 | |
| 126007402 | 12600740 | 2 | 20160708 | 0 |